Highlights of This Issue 3097

SPECIAL FEATURES

CCR 20th Anniversary Commentary

3099  CCR 20th Anniversary Commentary; Chimeric Antigen Receptors—From Model T to the Tesla
Patrick Hwu

CCR Translations

3102  Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy
Zachary A. Cooper, Alexandre Reuben, Jacob Austin-Breneman, and Jennifer A. Wargo
See related article, p. 3140

3105  Growth Factor Receptor Fusions Predict Therapeutic Sensitivity
Manmeet S. Ahluwalia and Jeremy N. Rich
See related article p. 3307

Molecular Pathways

3108  Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy
Diletta Di Mitri, Alberto Toso, and Andrea Alimonti

Reviews

3113  Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy
Atsushi Yonezawa, Suparna Dutta, Cariad Chester, Jeewon Kim, and Holbrook E. Kohrt

3121  Nanotechnology: Future of Oncotherapy
Kshipra M. Gharpure, Sherry Y. Wu, Chun Li, Gabriel Lopez-Berestein, and Anil K. Sood

CANCER THERAPY: CLINICAL

3131  Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning
Muriel Hannon, Yves Bugein, Grégory Ehx, Sophie Servais, Laurence Seidel, Carlos Graux, Johan Maertens, Tessa Kerre, Coline Daule, Muriel de Bock, Marianne Fillet, Aurélie Ory, Evelyne Willems, André Gothot, Stéphanie Humblet-Baron, and Frédéric Baron

3140  PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients
See related commentary, p. 3102

3149  Phase I Hepatic Immunotherapy for Metastases of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases
Steven C. Katz, Rachel A. Burga, Elise McCormack, Li Juan Wang, Wesley Mooring, Gary R. Point, Pranay D. Khare, Mitchell Thorn, Qianzhong Ma, Brian F. Stainsken, Earle O. Aassnali, Robin Davies, N. Joseph Espat, and Richard P. Junghans

3160  Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma
Jennifer R. Brown, Matthew S. Davids, Jordi Rodon, Pau Abrisqueta, Siddha N. Kasar, Joanne Lager, Jason Jiang, Coumaran Egile, and Earle O. Aasman

3170  Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate–Treated Castration-Resistant Prostate Cancer Patients
Xu S. Xu, Charles J. Ryan, Kim Stuyckens, Matthew R. Smith, Fred Saad, Thomas W. Griffin, Youn C. Park, Margaret K. Yu, An Vermeulen, Italo Poggesi, and Partha Nandy

3178  Biologic Activity of Autologous, Granulocyte–Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines
John M. Goldberg, David E. Fisher, George D. Demetri, Donna Neuberg, Stephen A. Allogia, Catia Fonseca, Yukoh Nahakaki, David Nemet, Chandrajit P. Raut, Suzanne George, Jeffrey A. Morgan, Andrew J. Wagner, Gordon J. Freeman, Jerome Ritz, Cecilia Lezcano, Martin Mihm, Christine Canning, F. Stephen Hodi, and Glenn Darnoff

PERSONALIZED MEDICINE AND IMAGING

3187  Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children’s Oncology Group
George S. Laszlo, Todd A. Alonzo, Chelsea J. Gudgeon, Kimberly H. Harrington, Robert B. Gerbing, Yi-Cheng Wang, Rhonda E. Ries, Charles J. Ryan, Kim Stuyckens, Matthew R. Smith, Fred Saad, Thomas W. Griffin, Youn C. Park, Margaret K. Yu, Yurie Vermeulen, Italo Poggesi, and Partha Nandy
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

Tony Mok, Yi-Long Wu, Jin Soo Lee, Chong-Jen Yu, Viroj Vijutsathaporn, Jennifer Sandoval-Tan, Guia Ladrera, Sumitra Thongprasert, Vichien Srimuninnimit, Meilin Liao, Yunzhong Zhu, Caicun Zhou, Fatima Fuerte, Benjamin Margono, Wei Wen, Julie Tsai, Matt Truman, Barbara Klughammer, David S. Shames, and Lin Wu

Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas

Misu Lee, Tobias Wiedemann, Claudia Gross, Ines Leinh€auser, Federico Roncaroli, Rickmer Braren, and Natalia S. Pellegata

Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma


HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL

Robbie Carson, Basak Celikci, Cathy Fenning, Arman Javadi, Nyree Crawford, Lucia Perez-Carbonell, Mark Lawler, Daniel B. Longley, Patrick G. Johnston, and Sandra Van Schaeybroeck

An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies


Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate

Preethi Korangath, Wei Wen Teo, Helen Sadik, Liangfeng Han, Noriko Mor, Charlotte M. Huijts, Honne Wildes, Sajothi Bheti, Zhe Zhang, Cesar A. Santa-Maria, Hualing Tsai, Chi V. Dang, Véred Stearns, Zaver M. Bhujwalla, and Sarasati Sukumar

The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment


XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A

Takahito Miyake, Sunila Pradeep, Sherry Y. Wu, Rajesh Rupainoole, Behrouz Zand, Yunfei Wen, Rahul M. Gharpure, Archana S. Nagaraja, Wei Hu, Min Soon Cho, Heather J. Dalton, Rebecca A. Previs, Morgan L. Taylor, Takeshi Hisamatsu, Yu Kang, Tao Liu, Sharon Shacham, Dilara McCauley, David H. Hawke, John E. Wiktoszowicz, Robert L. Coleman, and Anil K. Sood

A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs

Shang-Fan Yu, Bing Zheng, MaryAnn Go, Jeff Lau, Susan Spencer, Helga Baab, Robert Sotiano, Suchit Jhunjhunwala, Robert Cohen, Michele Caruso, Paul Polakis, John Flygare, and Andrew G. Polson

Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma

Anna Luisa Di Stefano, Alessandra Fucci, Veronique Frattini, Marianne Labussiere, Karina Mokhtari, Pietro Zoppoli, Yannick Marie, Aurelie Bruno, Blandine Boiselle, Marine Giry, Julien Savatovsky, Mehdi Touat, Hayat Belaid, Aurelie Kamoun, Ahmed Indalbah, Caroline Houllier, Feng R. Luo, Jean-Charles Soria, Josep Tabernero, Marica Eoli, Rosina Paterra, Stephen Yip, Kevin Petrecca, Jennifer A. Chan, Gaetano Finocchiaro, Anna Lasorella, Marc Sanson, and Antonio Javaron

Head-to-Head Comparison and Evaluation of 92 Plasma Protein Biomarkers for Early Detection of Colorectal Cancer in a True Screening Setting

Hongda Chen, Manuela Zucknick, Simone Werner, Phillip Knebel, and Hermann Brenner
Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment

Genetic Modulation of Neurocognitive Function in Glioma Patients
Yanhong Liu, Renke Zhou, Erik P. Sulman, Michael E. Scheurer, Nicholas Boehling, Georgina N. Armstrong, Spiridon Tsavachidis, Fu-Wen Liang, Carol J. Etzel, Charles A. Conrad, Mark R. Gilbert, Terri S. Armstrong, Melissa L. Bondy, and Jeffrey S. Wefel

POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

Correction: Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers

Correction: A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma

Correction: CTLA4 Blockade Broadens the Peripheral T-cell Receptor Repertoire

The heatmap shows expression of immune-related genes in endometrial cancers from the TCGA series. POLE proofreading-mutant tumors display evidence of a robust cytotoxic T-cell response. For details, see the article by van Gool and colleagues on page 3347 of this issue.